People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of Covid-19 vaccine, say the authors of a large-scale study that found many had poor antibody responses.
About:
The research measured antibody responses after vaccination with the Pfizer-BioNTech or the Oxford-AstraZeneca Covid-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people worldwide.
One of the brand names under which infliximab is marketed is Remicade, which has got regulatory clearance in India.
Anti-TNF drugs are effective treatments for immune-mediated inflammatory diseases, but by suppressing the immune system, they can reduce vaccine effectiveness and increase risk of serious infection, the researchers have suggested.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
